首页 | 本学科首页   官方微博 | 高级检索  
相似文献
 共查询到20条相似文献,搜索用时 1 毫秒
1.
OBJECTIVE: To investigate whether immunohistochemically demonstrated lymph node micrometastasis has a survival impact in patients with advanced gallbladder carcinoma (pT2-4 tumors). SUMMARY BACKGROUND DATA: The clinical significance of immunohistochemically detected lymph node micrometastasis recently has been evaluated in various tumors. However, few reports have addressed this issue with regard to gallbladder carcinoma. METHODS: A total of 1476 lymph nodes from 67 patients with gallbladder carcinoma (pN0, n = 40; pN1, n = 27) who underwent curative resection were immunostained with monoclonal antibody against cytokeratins 8 and 18. The results were correlated with clinical and pathologic features and with patient survival. RESULTS: Lymph node micrometastases were detected immunohistochemically in 23 (34.3%) of the 67 patients and in 37 (2.5%) of the 1476 nodes examined. Of the 37 nodal micrometastases, 21 (56.8%) were single-cell events, and the remaining 16 were clusters. Five micrometastases were detected in the paraaortic nodes. Clinicopathologic features showed no significant associations with the presence of lymph node micrometastases. Survival was worse in the 27 patients with pN1 disease than in the 40 with pN0 disease (5-year survival; 22.2% vs. 52.6%, P = 0.0038). Similarly, survival was worse in the 23 patients with micrometastasis than in the 44 without micrometastasis (5-year survival; 17.4% vs. 52.7%, P = 0.0027). Twenty-eight patients without any lymph node involvement had the best prognosis, whereas survival for the 11 patients with both types of metastasis was dismal. The grade of micrometastasis (single-cell or cluster) had no effect on survival. The Cox proportional hazard model identified perineural invasion, lymph node micrometastasis, and microscopic venous invasion as significant independent prognostic factors. CONCLUSIONS: Lymph node micrometastasis has a significant survival impact in patients with pN0 or pN1 gallbladder carcinoma who underwent macroscopically curative resection. Extensive lymph node sectioning with keratin immunostaining is recommended for accurate prognostic evaluation for patients with gallbladder carcinoma.  相似文献   

2.
3.
Background There is no consensus as to the impact of lymph node micrometastasis on survival of patients with gastric cancer. The aim of this study was to clarify the prognostic significance of lymph node micrometastasis in patients with histologically node-negative gastric cancer Methods Lymph nodes (n=2039) from 64 patients with histologically node-negative gastric cancer (T2, T3) were evaluated for micrometastasis. Three serial 5-μm sections of the resected lymph nodes were prepared for immunohistochemical staining with the anti-cytokeratin antibody CAM 5.2. Results Micrometastasis was found in 73 of 2039 nodes (4%) and 20 of 64 patients (32%). The 5-year survival rate was significantly lower for patients with lymph node micrometastasis than for those without lymph node micrometastasis (66% vs. 95%,P<.01). The 5-year survival rate was significantly lower when there were four or more positive micrometastatic nodes (94% vs. 29%,P <.01) and when there were extragastric micrometastatic nodes (89% vs. 53%,P<.01). Conclusions Lymph node micrometastasis was associated with poor outcome in patients with histologically node-negative gastric cancer. The number and the level of lymph node micrometastases are useful prognostic markers for deciding treatment strategies for additional therapy and follow-up.  相似文献   

4.
淋巴结转移是严重影响肝门部胆管癌(HCCA)患者手术预后的独立因素。淋巴结清扫是肝门胆管癌根治性切除术的重要内容,但关于术中淋巴结清扫的定义、范围及清扫数目仍存在较多争议。针对以上问题近年来国内外有较多研究,也有不少新观点。现有观点认为,术中常规对肝十二指肠韧带内、肝总动脉旁和胰头十二指肠后方的淋巴结(第12、8、13组)进行骨骼化清扫能够为HCCA患者带来明显的生存获益,但术中清扫腹腔干、腹主动脉及下腔静脉等周围淋巴结是否能为患者带来生存获益尚不明确;术中适当增加淋巴结清扫数目,不仅能够明显改善N0期患者的生存预后,还可提高阳性淋巴结的检出率,为疾病的分期获得足够的信息,但过度增加淋巴结清扫数目在实际操作中不仅难以实现,还可能导致术后并发症的发生率增加。因此,肝门部胆管癌术中淋巴结清扫相关问题尚需进一步研究。  相似文献   

5.
6.
目的 探讨淋巴结阴性的结直肠癌患淋巴结切除数目与预后的关系。方法 分析42例无显微镜下淋巴结转移的结直肠癌手术患的临床病理资料,将他们按淋巴结切除数目分为A组(50枚或以下)和B组(50枚以上),用Kaplan-Meier方法计算5年生存率,用χ^2检验两组间的差异。结果 B组5年生存率为100%,较A组(78.4%)明显增加,P=O.027;A组患肿瘤复发5例,其中5年内死亡3例;而B组患无肿瘤复发和死亡。结论 对无显微镜下淋巴结转移的结直肠癌患。尽量切除全数淋巴结可明显延长患的存活时间。  相似文献   

7.
进展期胃癌腹主动脉旁淋巴结微小转移与患者预后的关系   总被引:4,自引:0,他引:4  
目的研究进展期胃癌腹主动脉旁淋巴结的微小转移对于评价预防性淋巴结清除的意义。方法采用细胞角蛋白抗体,对47例进展期胃癌患者根治性手术清除的2339枚淋巴结(其中包括390枚腹主动旁淋巴结),进行免疫组织化学染色研究。结果常规HE染色发现390枚腹主动脉旁淋巴结中,95枚从14例患者中清除的淋巴结为转移阳性。剩余的295枚淋巴结中,有45枚从另15例患者中清除的淋巴结经免疫组化染色发现有微小转移。术后5年生存率在腹主动脉旁淋巴结转移阴性组为56.0%,微小转移组为25.2%,常规染色淋巴结转移组为9.0%。结论进展期胃癌存在较高的腹主动脉旁淋巴结微小转移率,预防性淋巴结清除对此类患者有效。  相似文献   

8.
9.
BACKGROUND: The purpose of this study was to investigate whether the presence of lymph node micrometastasis in pathological lymph node-negative (pN0) oesophageal squamous cell carcinoma had prognostic value. METHODS: Some 1840 lymph nodes were obtained from 50 patients with pN0 oesophageal squamous cell carcinoma who underwent curative resection of the primary tumour with systematic lymphadenectomy. These lymph nodes were examined immunohistochemically with anticytokeratin antibody (AE1/AE3). Lymph node micrometastases newly detected by immunohistochemistry were classified as micrometastasis. Additionally, lymph node micrometastases were classified into three stages: stage 1, one individual AE1/AE3-positive cell; stage 2, multiple individual positive cells; stage 3, one or multiple positive clusters. RESULTS: Micrometastases were detected in 20 patients (40 per cent). A higher stage of micrometastasis was associated with greater pathological tumour (pT) size (P = 0.023). Recurrent tumours developed in nine patients. However, the frequency of recurrence was similar in patients with, or without, micrometastasis (five of 20 and four of 30 patients respectively; P = 0.25). Twenty-three of 30 patients without micrometastasis survived, whereas 15 of 20 patients with micrometastasis were still alive (5-year overall survival 75 and 78 percent respectively, P = 0.91). Twenty-six of 30 patients without micrometastasis had no recurrence, whereas 15 of 20 patients with micrometastasis had no recurrence (5-year relapse-free survival 86 and 73 per cent respectively, P = 0.37). There was no significant difference in prognosis with respect to the stages of micrometastasis. Multivariate analysis also showed that micrometastasis was not an independent prognostic factor (P = 0.73). CONCLUSION: Immunohistochemical detection of lymph node micrometastasis may be an indicator of lymphatic dissemination of tumour cells. However, the presence of micrometastasis had no impact on the prognosis of node-negative patients with oesophageal squamous cell carcinoma.  相似文献   

10.
胃癌淋巴结微转移的临床意义   总被引:8,自引:1,他引:7  
目的 探讨淋巴结微转移与胃癌生物学行为及预后的关系。方法 采用免疫组织化学方法,用细胞角蛋白单抗MNF.116检测淋巴结微转移。结果 60例患者淋巴结微转移的阳性率为58.3%,微转移与肿瘤浸润深度及淋巴管侵犯密切相关(P〈0.05)。临床病理分期Ⅱ、Ⅲ期患者微转移的阳性率明显高于Ⅰ期(P〈0.05)。在Ⅰ期,阳性组的5年生存率明显低于阴性组(P〈0.05)。多变量分析表明淋巴结微转移是独立的预后  相似文献   

11.
目的 探讨肝门部胆管癌(HCC)的外科治疗特点及预后因素,以期进一步提高HCC外科疗效.方法 回顾性分析67例病理诊断为HCC患者的临床资料.结果 不同手术方法术后累计生存率差异显著(P<0.001).根治切除组1、3年生存率显著高于姑息切除组和单纯引流组,手术切除组较非手术切除组存活时间显著提高 (P<0.001).术前T分期和Bithmuth分型能指导手术切除率及术式选择.不同的T分期的手术切除率及切缘阴性率差异显著(P<0.001).分别对16个可能影响预后的因素进行单因素预后分析表明肿瘤大小、门静脉侵犯、局部浸润及转移、手术方法、UICC分期、改良T分期、淋巴结转移对预后有影响,统计学上有显著性差异(P<0.05).Cox模型多因素预后分析表明手术方法、UICC分期是两个独立预后因素.结论 根治性切除是最重要的预后因素,扩大手术范围能获得较好切缘无癌率,术前的T分期和Bismuth分型综合评估将有助于进一步在安全的范围内提高手术切除率及根治性切除率.  相似文献   

12.
目的分析总结肝内胆管细胞癌(ICC)不同N分期、外科治疗、淋巴结清扫范围及联合放化疗对其预后的影响。方法回顾性分析SEER数据库内4555例ICC患者的临床资料及随访结果。包括N0期患者3710例,N1患者845例,所有患者包括完整的TNM分期信息、生存时间及生存状态信息、手术相关信息及放化疗信息。以Kaplan-Meier法描述生存曲线,共描述120个月的生存情况,应用Log-rank检验法进行假设检验,观察不同N分期ICC患者总体预后差异,以及不同手术方式、是否清扫淋巴结、术后是否进行放化疗对不同N分期ICC患者预后的影响。偏态分布的计量资料用中位数(M)表示,计数资料用百分数(%)表示。结果N1期患者中位生存时间12个月,N0期患者中位生存时间15个月。在N0期患者中,未行手术的患者中位生存时间8个月,局部肿瘤毁损的患者中位生存时间26个月,手术切除的患者中位生存时间45~59个月;在N1期患者中,未行手术的患者中位生存时间9个月,局部肿瘤毁损的患者中位生存时间26个月,手术切除的患者中位生存时间14~22个月。N0期患者中,未进行淋巴结清扫的患者中位生存时间37个月,进行淋巴结清扫的患者中位生存时间46~55个月;N1期患者中,未进行淋巴结清扫的患者中位生存时间26个月,进行淋巴结清扫的患者中位生存时间18~20个月。N0期患者中,不进行联合放化疗的患者中位生存时间41~42个月,进行联合放化疗的患者中位生存时间43~46个月;N1期患者中,不进行联合放化疗的患者中位生存时间10~17个月,进行联合放化疗的患者中位生存时间23个月。结论ICC中N1期患者预后明显差于N0期患者,手术是治疗ICC的有效手段,同时应积极推荐常规清扫淋巴结,推荐N1期患者进行联合放化疗。  相似文献   

13.
Lymph node status is one of the most important predictors of survival in pancreatic ductal adenocarcinoma. Surgically resected pancreatic adenocarcinoma is often locally invasive and may invade directly into peripancreatic lymph nodes. The significance of direct invasion into lymph nodes in the absence of true lymphatic metastases is unclear. The purpose of this study was to retrospectively compare clinical outcome in patients with pancreatic ductal adenocarcinoma with direct invasion into peripancreatic lymph nodes with patients with node-negative adenocarcinomas and patients with true lymphatic lymph node metastasis. A total of 380 patients with invasive pancreatic ductal adenocarcinoma classified as pT3, were evaluated: ductal adenocarcinoma with true lymphatic metastasis to regional lymph nodes (248 cases), ductal adenocarcinoma without lymph node involvement (97 cases), and ductal adenocarcinoma with regional lymph nodes involved only by direct invasion from the main tumor mass (35 cases). Isolated lymph node involvement by direct invasion occurred in 35 of 380 (9%) patients. Overall survival for patients with direct invasion of lymph nodes (median survival, 21 mo; 5-year overall survival, 36%) was not statistically different from patients with node-negative adenocarcinomas (median survival, 30 mo; 5-year overall survival, 31%) (P=0.609). Patients with node-negative adenocarcinomas had an improved survival compared with patients with lymph node involvement by true lymphatic metastasis (median survival, 15 mo; 5-year overall survival, 8%) (P<0.001) regardless of the number of lymph nodes involved by adenocarcinoma. There was a trend toward decreased overall survival for patients with 1 or 2 lymph nodes involved by true lymphatic metastasis compared with patients with direct invasion of tumor into lymph nodes (P=0.056). However, this did not reach statistical significance. Our results indicate that patients with isolated direct lymph node invasion have a comparable overall survival with patients with node-negative adenocarcinomas as opposed to true lymphatic lymph node metastasis.  相似文献   

14.
常规检查淋巴结阴性No.7组胃癌患者的淋巴结微转移研究   总被引:4,自引:1,他引:4  
目的探讨常规病理检查无淋巴结转移的胃癌淋巴结微转移的特点,并分析微转移与各种临床病理因素的关系.方法应用淋巴结组织连续切片和端粒酶 RT-PCR ELISA方法检测 46例胃癌患者常规病理检查无淋巴结转移的 No.7组淋巴结 138个,并结合胃癌患者的临床病理资料进行统计学分析.结果本组 13例(28.3%) 32枚淋巴结(23.2%)经连续切片检出有微转移;而端粒酶阳性表达为 20例(43.5%) 49枚淋巴结(35.5%).端粒酶 RT-PCR ELISA检测敏感性为 100%,特异性为 84%,阳性预测值为 65%,阴性预测值为 100%,诊断准确率为 88%.淋巴结微转移与患者年龄、性别、原发肿瘤部位、组织学类型和转移淋巴结分型无关(P >0.05),但与原发肿瘤大体类型、大小及是否浸透浆膜有关(P< 0.05).结论对常规病理检查无淋巴结转移的胃癌患者,为客观评价胃癌临床病理分期及其预后,有必要监测其微转移,端粒酶 RT-PCR ELISA方法可以作为传统组织学检查方法的补充.  相似文献   

15.
甲状腺癌淋巴结微转移的研究   总被引:2,自引:0,他引:2  
目的:探讨MUC1检测在甲状腺癌淋巴结微转移的可靠性和敏感性。方法:对488例甲状腺疾病手术患者于术前24h用1%美兰1.0~2.0mL注射于甲状腺结节或周围腺体,术中显示蓝染淋巴结,采用RT-PCR法测定临床蓝染淋巴结中的MUC1。 结果:蓝染淋巴结显示率甲状腺癌为93%,良性病例为0。研究组80个蓝染淋巴结中发现有MUC1mRNA表达的为95%,与病理诊断率(86%)相比有提高(P<0.05);良性病变(阴性对照组)淋巴结均不存在MUC1mRNA的表达;阳性对照组的癌转移性淋巴结均存在MUC1mRNA的表达。结论:MUC1较病理检查敏感,PCR产物点杂交进一步证实MUC1作为PCR标志物有较好的可靠性。  相似文献   

16.
目的:探讨系统免疫炎症指数(SII)与接受外科手术治疗的肝门部胆管癌患者预后的关系。方法:回顾性分析2012年1月至2016年12月在郑州大学第一附属医院行外科手术治疗的181例肝门部胆管癌患者临床资料,其中男性119例,女性62例,平均年龄62.4岁。根据患者术前血常规计算SII。采用受试者工作特征(ROC)曲线确定...  相似文献   

17.
目的探讨影响肝内胆管细胞癌(ICC)患者根治性切除术后预后相关因素及腹腔淋巴结清扫范围对ICC患者术后预后的价值。方法回顾性分析从2013年10月至2017年10月在郑州大学附属肿瘤医院肝胆胰外科行根治性切除术的ICC患者临床资料,根据腹腔淋巴结清扫范围将患者分为未清扫组、常规清扫组和扩大清扫组,比较三组患者预后情况并釆用Cox逐步回归模型分析ICC患者预后的独立危险因素。结果共纳入178例患者,其中男性109例,女性69例,年龄30-81岁,平均59岁。根据腹腔淋巴结清扫范围,未清扫组纳入80例、常规清扫组纳入34例、扩大清扫组纳入64例。178例患者肝切除术后3年累积生存率为29.2%(52/178),总体中位生存时间25.8个月。未清扫组、常规清扫组、扩大清扫组的3年累积生存率分别为10.0%(8/80)、52.9%(18/34)、40.6%(26/64),三组整体生存率比较差异有统计学意义(P<0.05)。三组间两两比较结果显示:常规清扫组与扩大清扫组生存率比较,差异无统计学意义(P>0.05);未清扫组与常规清扫组、未清扫组与扩大清扫组生存率比较,差异有统计学意义(P<0.05)。单因素分析显示术前糖类抗原19-9(CA19-9)、肿瘤最大径、门静脉癌栓、腹腔淋巴结清扫范围与ICC患者预后有关(P<0.05);多因素分析显示术前CA19-9、肿瘤最大径、腹腔淋巴结清扫范围与患者生存有关(P<0.05)。结论CA19-9,肿瘤最大径、腹腔淋巴结清扫范围是ICC患者术后生存的独立危险因素。对于可行手术切除术的ICC患者,行腹腔淋巴结常规清扫术即可达到较好的预后效果,无需扩大腹腔淋巴结清扫范围。  相似文献   

18.
Objectives:   To analyze the effects of pathological T stage, grade, extent of surgery for primary tumor, and age group on the risk of developing lymph node metastasis in clinically node-negative penile cancer patients.
Methods:   We performed a retrospective analysis of 200 clinically node-negative penile cancer patients who were kept under surveillance, after treatment of the primary tumor in our institution. The primary outcome parameter was cytologically or histologically proven lymph node metastasis. Logistic regression analysis was used to compute odds ratios in univariate and multivariate settings.
Results:   Lymph node metastasis occurred in 31 patients at a median time of three months. Histological grade 3 and grade 2 tumors had a statistically significant increased odds ratio for lymph node metastasis, (7.1[ P  < 0.001] and 2.7 [ P  = 0.04], respectively), compared with grade 1 tumors. Although increasing pT stage was associated with increasing odds ratios, the differences were not statistically significant. Nor did the extent of surgery of the primary tumor or the age group significantly influence the risk of developing lymph node metastasis.
Conclusions:   Histological grade is the most significant parameter influencing the risk of lymph node metastasis in clinically node-negative penile cancer patients on surveillance. Patients with grade 3 and grade 2 tumors may benefit from elective inguinal lymphadenectomy.  相似文献   

19.
20.
淋巴结隐匿性微转移对肺癌预后影响的前瞻性研究   总被引:8,自引:0,他引:8  
目的 探讨肺癌纵隔淋巴结隐匿性微转移的诊断方法并评价其预后意义。方法 应用逆转录聚合酶链反应法 (RT PCR) ,对 5 8例非小细胞肺癌手术后病理检查阴性 (pN0 )的 2 4 2组纵隔淋巴结进行淋巴结中MUC1基因mRNA表达的再检测 ,诊断纵隔淋巴结隐匿性微转移。对病人进行随访 ,应用Ka plan Meier法计算生存率 ,Log Rank检验比较生存差别。 结果  16例病人的 2 3组纵隔淋巴结中检测到MUC1基因mRNA表达 ,诊断为纵隔淋巴结隐匿性微转移 ,常规病理检查的漏诊率为 2 7 6 % (16 /5 8例 )。病人的TNM分期由IA~IIB 期上调为IIIA 期。纵隔淋巴结隐匿性微转移组 3年生存率为 4 3 7% ,无转移组的 3年生存率为 73 8%。两组差异有显著统计学意义 (P <0 0 5 )。结论 应用RT PCR法检测纵隔淋巴结中MUC1基因mRNA的表达 ,可以诊断纵隔淋巴结隐匿性微转移 ,提高肺癌TNM分期的准确性 ;纵隔淋巴结隐匿性微转移与部分pN0 病人预后不良有关。  相似文献   

设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号